Sun Pharmaceutical Industries Limited — Important, 31-01-2025: Financial Result Updates

Consolidated financial results of Sun Pharmaceutical Industries Limited show a robust performance for the quarter and nine months ended December 31, 2024. Total revenue from operations reached ₹136,755 crore, reflecting a year-on-year growth of 10.5%. Key contributors to this growth include a 13.8% increase in India formulation sales, which now stand at ₹43,004 crore, and strong performance in Rest of World sales, up 21% to ₹2,590 crore.

Net profit for the quarter surged to ₹29,034 crore, an increase of 14.1% compared to ₹25,238 crore in the same period last year. This translates to an earnings per share (EPS) of ₹12.1. Growth drivers include a favorable product mix and market share gains, particularly in the Indian market, increasing from 7.8% to 8.2%.

Operational costs experienced a slight increase, with total expenses amounting to ₹103,485 crore, up 8.1% year-on-year. This includes rising costs in research and development, which totaled ₹8,450 crore.

Balance sheet health remains solid with total comprehensive income for the period at ₹30,337 crore, keeping debt levels manageable, which positions the company favorably for future opportunities.

Strategically, Sun Pharma is focusing on expanding its specialty portfolio and maintaining strong growth across all markets. Given the positive revenue trends, effective cost management, and a resilient market outlook, the stock is positioned for a buy perspective amidst a strengthening operational framework.